Evidence map›Paper›PMID 36952233›Full record

ArticleThe oncologist2023

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.

Mirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, Harrys A Torres, Lan Sun Wang, Bruno Palma Granwehr, Juhee Song, Hanna R F Dalla Pria, Van A Trinh, Isabella C Glitza Oliva and 9 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Mirella NardoDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9396-7864
Bulent YilmazDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Blessie Elizabeth NelsonDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Harrys A TorresDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lan Sun WangDepartment of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bruno Palma GranwehrDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Juhee SongDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8688-4104
Hanna R F Dalla PriaDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Van A TrinhDepartment of Melanoma Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isabella C Glitza OlivaDepartment of Melanoma Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sapna P PatelDepartment of Melanoma Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nizar M TannirDepartment of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed Omar KasebDepartment of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mehmet AltanDepartment of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sunyoung S LeeDepartment of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan MillerDepartment of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hao ZhangDepartment of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bettzy A StephenDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aung NaingDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundDespite the clinical benefit of immune checkpoint inhibitors (ICIs), patients with a viral hepatitis have been excluded from clinical trials because of safety concerns. The purpose of this study was to determine the incidence rate of adverse events (AEs) in patients with viral hepatitis who received ICIs for cancer treatment. MATERIALS AND

methodsWe conducted a retrospective study in patients with cancer and concurrent hepatitis B or C, who had undergone treatment with ICI at MD Anderson Cancer Center from January 1, 2010 to December 31, 2019.

resultsOf the 1076 patients screened, we identified 33 with concurrent hepatitis. All 10 patients with HBV underwent concomitant antiviral therapy during ICI treatment. Sixteen of the 23 patients with HCV received it before the initiation of ICI. The median follow-up time was 33 months (95% CI, 23-45) and the median duration of ICI therapy was 3 months (IQR, 1.9-6.6). Of the 33 patients, 12 (39%) experienced irAEs (immune-related adverse events) of any grade, with 2 (6%) having grade 3 or higher. None of the patients developed hepatitis toxicities.

conclusionICIs may be a therapeutic option with an acceptable safety profile in patients with cancer and advanced liver disease.

Indexed as

Hepatitis, Viral, HumanNeoplasmsAntiviral AgentsHumansImmune Checkpoint InhibitorsRetrospective StudiesAntiviral AgentsImmune Checkpoint Inhibitorsadvanced canceradvanced liver diseaseimmune checkpoint inhibitorssafetyviral hepatitis

Identifiers

PMID36952233
PMCPMC10400154
OpenAlexW4360600214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.